Benson MD, Dasgupta NR, Rao R. Diagnosis and screening of patients with hereditary transthyretin amyloidosis (Hattr): current strategies and guidelines. Ther Clin Risk Manag. 2020;16:749–58.

Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9).

​​Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B. Evaluation of mortality during long-term treatment with tafamidis for transthyretin amyloidosis with polyneuropathy: clinical trial results up to 8.5 years. J Mol Biol. 1974 Sep 5;88(1):1–12.

Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785–93.

Article  PubMed  Google Scholar 

• Kaku MC, Bhadola S, Berk JL, Sanchorawala V, Connors LH, Lau KHV. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays. Amyloid. 2022;29(3):184–9. Retrospective study detailing early neurologic manifestations of hereditary transthyretin amyloidosis.

Article  CAS  PubMed  Google Scholar 

Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc. 2012;60(4):765–74.

Article  PubMed  PubMed Central  Google Scholar 

• Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: thaos (transthyretin amyloid outcome survey). J Am Coll Cardiol. 2016;68(2):161–72. Summarizes findings from the THAOS registry, characterizing demographics, genetic features and phenotypes of U.S. and international populations of patients with ATTRv amyloidosis.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Connors LH, Prokaeva T, Lim A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158(4):607–14.

Article  CAS  PubMed  Google Scholar 

Blake CC, Geisow MJ, Swan ID, Rerat C, Rerat B. Structure of human plasma prealbumin at 2–5 A resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J Mol Biol. 1974;1–12.

Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1).

Parsaik AK, Singh B, Altayar O, et al. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med. 2013;28(11):1496–503.

Article  PubMed  PubMed Central  Google Scholar 

Singer W, Opfer-Gehrking TL, Mcphee BR, Hilz MJ, Bharucha AE. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. Clinical Trial J Neurol Neurosurg Psychiatry. 2003;74(9):1294–8.

Article  CAS  PubMed  Google Scholar 

Winge K, Rasmussen D, Werdelin LM. Constipation in neurological diseases. J Neurol Neurosurg Psychiatry. 2003;74(1):13–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nilsson SF, Rask L, Peterson PA. Studies on thyroid hormone-binding proteins. II. Binding of thyroid hormones, retinol-binding protein, and fluorescent probes to prealbumin and effects of thyroxine on prealbumin subunit self association. J Biol Chem. 1975;250(21):8554–63.

J Herbert Wilcox JN,Pham K-TC, et al. Transthyretin Neurology. 1986 ;36(7): 900

Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121(1):73–85.

Article  CAS  PubMed  Google Scholar 

•• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31. Study demonstrating efficacy of inotersen, a TTR silencer.

Article  CAS  PubMed  Google Scholar 

Benson MD, Pandey S, Witchell D, et al. Antisense oligonucleotide ttherapy for TTR amyloidosis. Amyloid. 2011;18(sup1):60–60.

Article  PubMed  Google Scholar 

Ackermann EJ, Guo S, Benson MD, et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid. 2016;23(3):148–57.

Article  CAS  PubMed  Google Scholar 

Coelho T, Ando Y, Benson MD, et al. Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. Neurol Ther. 2021;10(1):375–89.

Article  PubMed  PubMed Central  Google Scholar 

Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–29.

Article  CAS  PubMed  Google Scholar 

Suhr OB, Coelho T, Buades J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis. 2015;10(1).

•• Coelho T, Adams D, Conceição I, et al. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet J Rare Dis. 2020;15(1). An extension study detailing long-term outcomes of patisiran.

•• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.

Quan D, Obici L, Berk JL, et al. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial. Amyloid. 2023;30(1):49-58.

•• Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 2023;30(1):1-9. Landmark study on efficacy of vutrisiran, a TTR silencer.

• Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493–502. Landmark article on novel CRISPR technology for TTR amyloidosis.

Article  CAS  PubMed  Google Scholar 

Finn JD, Smith AR, Patel MC, et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 2018;22(9):2227–35.

Article  CAS  PubMed  Google Scholar 

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022.

•• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–67. Study demonstrating efficacy of diflunisal, a TTR stabilizer.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda SI. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015;22(2):79–83.

Article  CAS  PubMed  Google Scholar 

Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial. Neurology. 2012;79(8):785–92. Study assessing efficacy of tafamidis.

Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Waddington M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23(3):178–83.

Lozeron P, Théaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013;20(12):1539–45.

Article  CAS  PubMed  Google Scholar 

Huber P, Flynn A, Sultan MB, et al. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy. Amyloid. 2019;26(4):203–9.

Article  CAS  PubMed  Google Scholar 

Monteiro C, Martins da Silva A, Ferreira N, et al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid. 2018;25(2):120–8.

Ueda M, Misumi Y, Mizuguchi M, et al. SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem. 2009;55(6):1223–7.

Article  CAS  PubMed  Google Scholar 

Coelho T, Carvalho M, Saraiva M, Alves C, Almeida M, Costa P, Almeida, Araùjo PA. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR MET 30 and TTR MET 119. 1993

Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol. 2012;421(2–3):185–203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fox JC, Hellawell JL, Rao S, et al. First-in-human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers. Clin Pharmacol Drug Dev. 2020;9(1):115–29.

Article  CAS  PubMed  Google Scholar 

Judge DP, Heitner SB, Falk RH, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285–95.

Article  CAS  PubMed  Google Scholar 

Pinheiro F, Varejão N, Esperante S, et al. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. FEBS J. 2021;288(1):310–24.

Article  CAS  PubMed  Google Scholar 

Gamez J, Salvadó M, Reig N, et al. Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study#. Amyloid. 2019;26(2):74–84.

Article  CAS  PubMed  Google Scholar 

Sant’Anna R, Gallego P, Robinson LZ, et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun. 2016;7.

Fernandes L, Cardim-Pires TR, Foguel D, Palhano FL. Green tea polyphenol epigallocatechin-gallate in amyloid aggregation and neurodegenerative diseases. Front Neurosci. 2021;15.

Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, Zorzoli I, Marinone MG, Garini P, et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils- inhibition of amyloidogenesis. Proc Natl Acad Sci USA. 1995;92:2959–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cardoso I, Merlini G, Saraiva MJ. 4 ′-iodo-4′-Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 2003;17(8):803–9.

Article  CAS  PubMed  Google Scholar 

Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. In: Amyloid. 2012;Suppl1:34–6.

Suhr O GMM da SA et al. Neurological and cardiac improvements with PRX004 in amyloidosis patients: results of a phase 1 study, 2021 emerging science abstracts. In: AAN Annual Meeting Abstracts. Neurology. 2021;e2783–8.

Saelices L, Nguyen BA, Chung K, et al. A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils. J Biol Chem. 2019;294(15):6130–41.